The performance of Horus Pharma is based on a reasoned dynamic of Research and Development, recruitment and international conquest
Recording two-digit growth since its inception, Horus Pharma ended the year 2016 with a turnover of €40.80 million. A good progress which is expected to continue with a forecast turnover of €49 million next year. With the launch of its firts european subsidiaries and supported by a growing network of international distributors, the Group expects to achieve 50% of its turnover from exports within the next 3 to 5 years. 10% of sales invested in R&D to gradually reach 15% over the next five years.
Horus Pharma growth is measured through concrete results in terms of hiring, product portfolio expansion and performance at the national and international levels:
In the span of 3 years between 2013 and 2016, the number of Horus Pharma employees has doubled growing to nearly 150 employees today.
With two to three new product launches per year, the laboratory’s product portfolio has grown to 45 specialities.
The position Horus Pharma holds in the National Ranking for SMEs and most successful independent French ETI